- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis | 223 | GlobeNewswire (Europe) | More than 94% of participants achieved a =5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing... ► Artikel lesen | |
| 28.09. | Stifel reiterates Vor Biopharma stock rating on telitacicept potential | 2 | Investing.com | ||
| 23.09. | Vor Biopharma: Telitacicept soll mit dualem Wirkansatz bei Autoimmunerkrankungen punkten | 4 | Investing.com Deutsch | ||
| 09.09. | Vor Biopharma auf dem Citigroup Biopharma-Gipfel: Pipeline-Offensive für Telitacicept | 2 | Investing.com Deutsch | ||
| 08.09. | Vor Bio auf Wells-Fargo-Konferenz: MG-Medikament zielt auf breiten Wirkvorteil ab | 17 | Investing.com Deutsch | ||
| 04.09. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 8 | GlobeNewswire (USA) | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 12.08. | Vor Biopharma reports Q2 results | 2 | Seeking Alpha | ||
| 11.08. | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 1.662 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| 11.08. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 7 | SEC Filings | ||
| 03.08. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 07.07. | Vor Bio appoints David Zaccardelli to board of directors | 1 | Investing.com | ||
| 07.07. | Vor Bio beruft erfahrenen Pharma-Manager David Zaccardelli in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 07.07. | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | 300 | GlobeNewswire (Europe) | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| 07.07. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China | 1 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China | 698 | GlobeNewswire (Europe) | First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published... ► Artikel lesen | |
| 01.06. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Vor Biopharma reports Q1 results | 3 | Seeking Alpha |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,537 | -0,04 % | PAUKENSCHLAG: Steht die Valneva-Aktie vor einer Kursexplosion? - Handeln Sie vor Montag! | ||
| CRISPR THERAPEUTICS | 48,940 | -0,56 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 | ||
| PALATIN TECHNOLOGIES | 9,330 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,902 | -0,99 % | H.C. Wainwright raises Ocugen stock price target on Bahamas approval | ||
| CLINUVEL | 5,044 | +0,98 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding | ||
| EDITAS MEDICINE | 2,210 | -5,15 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,095 | -0,90 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,520 | -0,13 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,200 | -2,31 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| GERON | 1,095 | +3,06 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,500 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,200 | 0,00 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| VERASTEM | 6,924 | +1,17 % | Verastem presents new data on ovarian cancer drug combination | ||
| FATE THERAPEUTICS | 2,038 | 0,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 18,690 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.